Advertisement

15-ICML: Can Serum Biomarkers Provide Prognostic Information in Relapsed Mantle Cell Lymphoma?

Advertisement

Key Points

  • The IMMRay platform analyzed 380 different epitopes among approximately 150 unique proteins.
  • Preliminary results showed that, at baseline, a signature of six to eight relevant proteins were associated with progression-free survival; however, researchers wrote that further investigations are needed to validate this in an independent cohort of patients.

Data presented by Lokhande et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 360) focused on noninvasive strategies to guide patient stratification for relapsed mantle cell lymphoma. Researchers used an antibody-based platform to identify serum proteins in patients treated in the Nordic MCL6 PHILEMON trial.

Methods

The PHILEMON trial looked to determine the efficacy of ibrutinib/lenalidomide/rituximab in relapsed or refractory mantle cell lymphoma. Sequential serum samples from 44 patients in the trial were processed on the IMMRay platform at 4 times during trial treatment: at baseline and 12, 24, and, 36 weeks of treatment.

The IMMRay platform analyzed 380 different epitopes among approximately 150 unique proteins. Spot recognition and raw data processing were performed using standard operating procedure according to IMMRay guidelines. Normalization and further bioinformatic and biostatistical analysis were performed using standard tools and several other in-house software programs developed in conjunction with the experimental platform.

Findings

Preliminary results showed that, at baseline, a signature of six to eight relevant proteins were associated with progression-free survival. However, researchers wrote that further investigations are needed to validate this in an independent cohort of patients. Next steps in the research will aim to determine whether additional prognostic and biologic information related to treatment can be derived by comparing samples at baseline, cycle 4, and further treatment.

The researchers concluded, “We have shown that prognostic information can be derived from serum samples collected from [patients with] relapsed mantle cell lymphoma. To our knowledge, this is the first time that an antibody-based array is used as a tool to assess the possibility of developing serum-based signatures useful for treatment selection in relapsed [patients with mantle cell lymphoma].”

Disclosure: For full disclosures of the study authors, visit lymphcon.ch.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement